Abstract: An composition containing transglutaminase and collagen. The composition can be used to prepare bound food, preferably without the use of allergy-causing casein proteins.

Abstract: Novel dipeptide derivatives, such as N-3,3-dimethylbutyl-.alpha.-L-aspartyl-.alpha.-methyl-L-phenylalanine methyl ester and N-3,3-dimethylbutyl-.alpha.-L-aspartyl-.alpha.-methyl-L-tyrosine methyl ester, and sweetening agents comprising, as the active ingredient, anyone of the derivatives and their salts, being low-calorie sweetening agents which are excellent in stability, safety and degree of sweetness, are provided. The products to have been sweetened, comprising such above sweetening agents are also provided.

Abstract: The present invention relates to hepatitis B virus (hereinafter it refers to HBV) polymerase containing a histidine tag, RNase H enzyme derived from HBV polymerase and processes for preparation thereof.More particularly, the present invention relates to recombinant HBV polymerase, its RNase H domain with enzyme activity, expression vectors producing the enzymes in E. coli and processes for preparing the HBV polymerase and the RNase H enzyme which can be easily purified due to their histidine tags.And the present invention relates to uses of the HBV polymerase and the RNase H enzyme for screening antiviral agents.

Abstract: A purified thermostable enzyme is derived from the eubacterium Thermosipho africanus. The enzyme has DNA polymerase, activity reverse transcriptase activity, and optionally 5'.fwdarw.3' and/or 3'.fwdarw.5' exonuclease activity. The enzyme can be native or recombinant, and may be used with primers and nucleoside triphosphates in a temperature-cycling chain reaction where at least one nucleic acid sequence is amplified in quantity from an existing sequence.

Abstract: The invention provides a human lysophospholipase (NHLP) and polynucleotides which identify and encode NHLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of NHLP.

Abstract: This invention relates to a recombinant deoxyribonucleic acid (DNA) isolatable from Aspergillus, preferably Aspergillus foetidus, wherein it codes for a lysophospholipase (LPL) and has the nucleotide sequence for mature LPL stated in SEQ ID NO:1 or a nucleotide sequence derived therefrom, which hybridises under stringent conditions with the nucleotide sequence for mature LPL stated in SEQ ID NO:1. The invention also relates to vectors, to transformed host organisms and to processes for the production of LPL. The invention also provides enzyme products for the production of maltose syrup and products produced in this manner.

Abstract: A method of producing a clouding agent from citrus membrane and/or peel for use in fruit juices and soft drink beverages comprising the sequential steps of mincing or chopping the citrus membrane and/or peel, forming a slurry of water and the minced or chopped citrus membrane and/or peel, pasteurizing the slurry of water and minced or chopped citrus membrane and/or peel to deactivate the constitutive enzymes, heating the slurry of water and minced or chopped citrus membrane and/or peel to deactivate/destroy the enzymes and bacteria, mixing pectolytic and/or cellulytic enzymes into the slurry of water and minced or chopped citrus membrane and/or peel, separating the citrus cellular debris from the slurry of water and minced or chopped citrus membrane and/or peel to produce a liquid effluent of clouding material with a range of particle sizes compatible with stable suspensions, pasteurizing the liquid effluent of clouding material to deactivate/destroy the pectolytic and/or cellulytic enzymes and concentrating

Abstract: Process for the continuous preparation of a fermented milk in which (1) a milk fermented by lactic acid bacteria is prepared in a first device, the fermented milk being subjected to stirring and pH conditions such that syneresis of the milk does not occur, the pH being regulated by the continuous addition of unfermented milk to the first device and continuously drawing off fermented milk from the first device; (2) in a second, post-acidification device, the fermented milk drawn off from the first device is cooled to a temperature of less than 15.degree. C. so as to subject the fermented milk to a post-acidification, the residence time of the fermented milk in the second device being adjusted so that at the outlet of the latter, the pH of the fermented milk is less than pH 4.7; and (3) a fermented milk having a pH of less than pH 4.7 is continuously drawn off from the second device.

Abstract: The present invention relates to isolating DNA coding for DNA polymerase I from Thermomicrobium roseum, expressing the T. roseum DNA polymerase I gene in E. coli and purifying the recombinant T. roseum DNA polymerase I from E. coli cell extract.

Abstract: A polypeptide possessing maltotetraose-forming amylase activity with a revealed amino acid sequence. The polypeptide has features that it acts on starch to mainly produce maltotetraose, and that it has a molecular weight of 50,000.+-.10,000 when electrophoresed on SDS-polyacrylamide gel.The polypeptide can be advantageously used in industrial process.

Abstract: The present invention relates to a selective cytotoxic RNase reagent. The reagent comprises a toxic moiety that is an RNase linked to a recognition moiety that binds a specific cell surface marker. Binding of the recognition moiety to a surface marker on a cell allows the toxic moiety to selectively kill the cell. To reduce immunogenicity, preferably the toxic moiety and the recognition moiety of the conjugate are endogenous to the species in which the reagent is intended for use. Cytotoxic reagents intended for use in humans preferably have as the toxic moiety a human ribonuclease, such as angiogenin, and as the recognition moiety as humanized chimeric antibody. The human ribonuclease and chimeric antibody preferably form a fused protein. The present invention also relates to pharmaceutical compositions including the cytotoxic reagent as well as treatment methods involving the use of the cytotoxic reagent.

Abstract: This invention relates to DNA containing a gene encoding uricase, a plasmid having said DNA, a transformant containing said plasmid, and a process for producing uricase by using said transformant.

Abstract: Thioredoxin, a small dithiol protein, is a specific reductant for major food proteins, allergenic proteins and particularly allergenic proteins present in widely used foods from animal and plant sources. All targeted proteins contain disulfide (S--S) bonds that are reduced to the sulfhydryl (SH) level by thioredoxin. The proteins are allergenically active and less digestible in the oxidized (S--S) state. When reduced (SH state), they lose their allergenicity and/or become more digestible. Thioredoxin achieved this reduction when activated (reduced) either by NADPH via NADP-thioredoxin reductase (physiological conditions) or by dithiothreitol, a chemical reductant. Skin tests and feeding experiments carried out with sensitized dogs showed that treatment of the food with reduced thioredoxin prior to ingestion eliminated or decreased the allergenicity of the food. Studies showed increased digestion of food and food proteins by pepsin and trypsin following reduction by thioredoxin.

Abstract: DNAs which encode human LTC.sub.4 synthase and expression vectors comprising such DNAs are provided. DNAs encoding human LTC.sub.4 synthase may be used in assay methods of the invention for detecting LTC.sub.4 synthase inhibitors. Nucleic acid probes capable of identifying cDNAs and/or genomic DNAs encoding LTC4 synthase, as well as LTC.sub.4 antisense oligonucleotides and analogs which may be administered to viable cells to inhibit production of LTC.sub.4 synthase are also provided.

Abstract: A process for producing pampered whey protein. The pH of whey protein is carefully controlled and maintained substantially constant during processing to produce a protein resistance to precipitation during sterilization.

Abstract: The invention relates to a substantially pure thermostable DNA polymerase from Thermotoga (Tne and Tma) and mutants thereof. The Tne DNA polymerase has a molecular weight of about 100 kilodaltons and is more thermostable than Taq DNA polymerase. The mutant DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'.fwdarw.5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'.increment.3' exonuclease activity of said DNA polymerase; (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides. The present invention also relates to the cloning and expression of the wild type or mutant DNA polymerases in E. coli, to DNA molecules containing the cloned gene, and to host cells which express said genes.

Abstract: A method for processing a protein, a non-proteinaceous amino acid polymer, or a non-proteinaceous amino acid polymer, or a peptide or derivatives thereof having a crosslinked structure, which entails contacting glutamine and lysine residues in a protein, a non-proteinaceous amino acid polymer, a peptide or derivatives thereof with a transglutaminase obtained from Bacillus subtilus to form intermolecular or intramolecular, crosslinked .epsilon.(.delta.-Glu)-Lys bonds between or in the molecules of the protein, non-proteinaceous amino acid polymer, peptide or derivatives thereof, wherein the transglutaminase has the physicochemical properties described herein.

Abstract: The invention provides purified thermostable enzymes derived from various extremophilic prokaryotic organisms. The enzymes have polymerase activity and can be used to catalyze DNA synthesis by addition of deoxynucleotides to the 3' end of a polynucleotide chain, using a complementary polynucleotide strands as a template.

Abstract: One or more compounds selected from among oleanolic acid, ursolic acid, and polygodial added to a flavored product to reduce an aftertaste in the product and enhance its sweetness. This flavored product additive is added to diet beverages and flavored products at an amount effective to reduce the aftertaste of the artificial sweetener and improve the sweet flavor. This amount is from 0.1 ppm to 1000 ppm with respect to the artificial sweetener. The present invention also includes a diet drink which contains polygodial, oleanolic acid, or ursolic acid at 0.001 ppb to 10 ppm with respect to the artificial sweetener, for improving or reducing an aftertaste from the artificial sweetener and also to improve the sweetness of the flavor.

Abstract: An enzyme--ice cream composition in which a sterilized acid-sensitive lactase enzyme hydrolyzes lactose after the ice cream is frozen to a temperature less than twenty degrees Fahrenheit.